Xeris is a National Supporter of the American Diabetes Association. The 2024 Standards of Care by the American Diabetes Association emphasizes the importance of prescribing glucagon for individuals with diabetes who are at a heightened risk for level 2 and 3 hypoglycemia patients on insulin and sulfonylureas and states that ready-to-use glucagon formulations may be beneficial in view of safety, efficacy, and ease of use. Xeris takes pride in supporting the ADA's efforts to ensure that not only people with diabetes, but also those who provide support are aware of the availability of ready-to-use glucagon options.

View the website